NCT03848312 · Phase 3 · RECRUITING
Preventing Alzheimer's With Cognitive Training
This Phase 3 trial is testing whether a specific type of computerized brain training — called speed of processing training — can delay the onset of mild cognitive impairment or dementia in healthy adults 65 and older. Phase 3 means the intervention has shown earlier promise and researchers are now checking whether it works at a larger scale. Participants do cognitive exercises on a computer over three years. No drugs involved.
You may qualify if
- Be age 65 or older at time of consent
- Have ability to speak and understand English or Spanish
- Report adequate sensorimotor capacity to perform the computer exercises
- Report adequate visual capacity to read from a computer screen at a typical viewing distance
- Show adequate auditory capacity to understand conversational speech
- Show adequate motor capacity to touch a computer screen or control a computer mouse.
- Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the Montreal Cognitive Assessment score >=26.
- Have adequate mental health (no self-reported diagnoses of mental illness that would interfere with ability to comply with study procedures or benefit from intervention)
- Wiling to complete all study activities
- Ability to understand study procedures and comply with them for the length of the study
You're excluded if
- Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition
- Previous participation in a cognitive training study
- Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions
- Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., congestive heart failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing chemotherapy or radiation).
- Self-reported use of medications typically prescribed for dementia such as: Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, aducanumab, Aduhlem.
- Completion of 10 or more hours of a computerized cognitive training program in the last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ, Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim
- Severe depressive symptoms (Geriatric Depression Scale score >=5)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-09-26